.png)
NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...
55W 14th St Ste 101, Helena, Montana, 59601, US
+1(406)-319-1601
news.in.usa@olahost.top
Copyright © 2024 olascience. All Rights Reserved
